01—Abstract
Summary
Summary of the 8-K filed March 26, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation filed this Current Report on Form 8-K on March 26, 2026 to disclose executive title changes announced March 25, 2026, effective immediately.
Pablo J. Cagnoni's title changed to President, Incyte and Global Head of Research and Development, replacing William J. Meury as President; Meury remains Chief Executive Officer and a member of the Board of Directors.
Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, and Mohamed Issa became Executive Vice President and Head of U.S. Commercial, with expanded responsibility for U.S. Immunology as the U.S. Oncology and Immunology business units are integrated into a single U.S. commercial organization. The filing states there were no changes to the compensation arrangements of any of the affected executives in connection with these title changes.
The press release also states that Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The announcement is framed around supporting the company's strategic focus, long-term growth plans, and launch execution. The filing cites R&D progress under Dr. Cagnoni's leadership, including the mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs, and states that the U.S. commercial integration is intended to drive effective launch execution.
02—Key points
Key Highlights
- Pablo J. Cagnoni named President, Incyte and Global Head of Research and Development, replacing William J. Meury as President
- William J. Meury remains Chief Executive Officer and a member of the Board of Directors
- Steven H. Stein's title changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development, overseeing late-stage programs across Hematology, Oncology and Immunology and Global Medical Affairs
- Mohamed Issa's title changed to Executive Vice President and Head of U.S. Commercial, with expanded responsibility for U.S. Immunology
- U.S. Oncology and U.S. Immunology business units are being integrated into a single U.S. commercial organization
- Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period
- No changes to compensation arrangements for the Impacted Executives in connection with the title changes
03—Questions
Frequently Asked Questions
Who is leading Incyte's R&D function after these changes?
Pablo J. Cagnoni, M.D., is now President, Incyte and Global Head of Research and Development. He retains R&D responsibility and also supports enterprise-wide strategic planning and operational execution.
Is CEO Bill Meury leaving Incyte?
No. The filing states that Mr. Meury remains Chief Executive Officer and a member of the Company's Board of Directors. He is no longer President, Incyte, a title now held by Dr. Cagnoni.
Why are the U.S. Oncology and U.S. Immunology businesses being combined?
According to the press release, the units are being integrated into a single U.S. commercial organization to support strategic alignment and execution for new product launches, operational effectiveness and standardization of best practices.
Did these leadership changes affect executive pay?
The filing states there were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes.
Which executive departure was disclosed alongside these changes?
The press release states that Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.
04—Continue